Controlled-Release,Pegylation,Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs

Abstract

Spanish

French

OBJECTIVE:

To review recent developments in novel injectable drug delivery mechanisms and outline the advantages and disadvantages of each.

DATA SOURCES:

A MEDLINE (1995–January 2000) search using the terms polyethylene glycol, liposomes, polymers, polylactic acid, and controlled release was conducted. Additional references were identified by scanning bibliographies.

STUDY SELECTION AND DATA EXTRACTION:

All articles were considered for inclusion. Abstracts were included only if they were judged to add critical information not otherwise available in the medical literature.

DATA SYNTHESIS:

A number of systems that alter the delivery of injectable drugs have been developed in attempts to improve pharmacodynamic and pharmacokinetic properties of therapeutic agents. New drug delivery systems can be produced either through a change in formulation (e.g., continuous-release products, liposomes) or an addition to the drug molecule (e.g., pegylation). Potential advantages of new delivery mechanisms include an increased or prolonged duration of pharmacologic activity, a decrease in adverse effects, and increased patient compliance and quality of life. Injectable continuous-release systems deliver drugs in a controlled, predetermined fashion and are particularly appropriate when it is important to avoid large fluctuations in plasma drug concentrations. Encapsulating a drug within a liposome can produce a prolonged half-life and a shift of distribution toward tissues with increased capillary permeability (e.g., tumors, infected tissue). Pegylation provides a method for modification of therapeutic proteins to minimize many of the limitations (e.g., poor stability, short half-life, immunogenicity) associated with these agents.

CONCLUSIONS:

Pegylation of therapeutic proteins is an established process with new applications. However, not all pegylated proteins are alike, and each requires optimization on a protein-by-protein basis to derive maximum clinical benefit. The language required to describe each pegylated therapeutic protein must be more precise to accurately distinguish each protein's differential pharmacologic properties.

Keywords

polyethylene glycol liposomes polymers polylactic acid controlled release

Get full access to this article

View all access options for this article.

References

Nucci

Shorr

Abuchowski

. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 1991;6:133–51.

Fuertges

Abuchowski

. The clinical efficacy of polyethylene glycol-modified proteins. J Controlled Release 1990;11:139–48.

Okada

Toguchi

. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995;12:1–99.

Ogawa

. Injectable microcapsules prepared with biodegradable poly(α-hydroxy) acids for prolonged release of drugs. J Biomater Sci Polym Ed 1997;8:391–409.

Yewey

Duysen

Cox

Dunn

. Delivery of proteins from a controlled release injectable implant. Pharm Biotechnol 1997;10:93–117.

Eppstein

Longenecker

. Alternative delivery systems for peptides and proteins as drugs. Crit Rev Ther Drug Carrier Syst 1988;5:99–139.

Okada

. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997;28: 43–70.

Sandow

Stoeckemann

Jerabek-Sandow

. Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. J Steroid Biochem Mol Biol 1990;37:925–31.

Okada

Inoue

Heya

Ueno

Ogawa

Toguchi

. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm Res 1991;8:787–91.

10.

Johnson

Cleland

Lee

Charnis

Duenas

Jaworowicz

A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996;2:795–9.

11.

Cleland

Jones

AJS

. Stable formulations of recombinant human growth hormone and interferong for microencapsulation in biodegradable microspheres. Pharm Res 1996;13:1464–75.

12.

Cleland

Mac

Boyd

Yang

Duenas

Yeung

The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 1997;14:420–5.

13.

Heya

Mikura

Nagai

Miura

Futo

Tomida

Controlled release of thyrotropin releasing hormone from microspheres: Evaluation of release profiles and pharmacokinetics after subcutaneous administration. J Pharm Sci 1994;83:798–801.

14.

Calis

Jeyanthi

Tsai

Mehta

DeLuca

. Adsorption of salmon calcitonin to PLGA microspheres. Pharm Res 1995;12:1072–6.

15.

Storm

Crommelin

DJA

. Colloidal systems for tumor targeting. Hybridoma 1997;16:119–25.

16.

Allen

. Liposomes. Opportunities in drug delivery. Drugs 1997;54 (suppl 4):8–14.

17.

Bakker-Woudenberg

IAJM

Storm

Woodle

. Liposomes in the treatment of infections. J Drug Target 1994;2:363–71.

18.

Gabizon

Martin

. Polyethylene glycolcoated (pegylated) liposomal doxorubicin. Drugs 1997;54(suppl 4):15–21.

19.

Khalifa

Dodds

Rampling

Paterson

Murray

. Liposomal distribution in malignant glioma: Possibilities for therapy. Nucl Med Commun 1997;18:17–23.

20.

Wasan

Lopez-Berestein

. The past, present, and future uses of liposomes in treating infectious diseases. Immunopharmacol Immunotoxicol 1995;17:1–15.

21.

Margalit

. Liposome-mediated drug targeting in topical and regional therapies. Crit Rev Ther Drug Carrier Syst 1995;12:233–61.

22.

Shek

Suntres

Brooks

. Liposomes in pulmonary applications: Physiochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 1994;2:431–42.

23.

Leander

Höglund

Kloster

Børseth

. New liposomal liver-specific contrast for CT: First human Phase I clinical trial assessing efficacy and safety. Acad Radiol 1998;5(suppl 1):S6–8.

24.

Höglund

Leander

Hustvedt

Kloster

Børseth

. Human pharmacokinetics and modeling of the concentration—attenuation relationship of a new liposomal liver-specific contrast agent for CT. Acad Radiol 1998;5(suppl 1):S47–8.

25.

Leenders

de-Marie

. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996;10:1570–5.

26.

Gabizon

. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994;8:431–50.

27.

Hiemenz

Walsh

. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996;22(suppl 2):S133–44.

28.

Prentice

Hann

Herbrecht

Aoun

Kvaloy

Catovsky

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711–8.

29.

Szebeni

. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998;15:57–88.

30.

Francis

Delgado

Fisher

Malik

Agrawal

. Polyethylene glycol modification: Relevance of improved methodology to tumour targeting. J Drug Target 1996;3:321–40.

31.

Alberts

Garcia

. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997;54(suppl 4):30–5.

32.

Amantea

Forrest

Northfelt

Mamelok

. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 1997;61:301–11.

33.

Muggia

. Clinical efficacy and prospects for the use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997;54(suppl 4):22–9.

34.

Suzuki

Watanabe

Masuko

Hashimoto

. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with polyethylene glycol. Biochem Biophys Acta 1995;1245:9–16.

35.

Nam

Kim

Ahn

Park

. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: Targeting to B16BL6, HRT-18 cancer cells. Oncol Res 1999;11:9–16.

36.

Pagnan

Montaldo

Pastorino

Raffaghello

Kirchmeier

Allen

GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 1999;81:268–74.

37.

Bailon

Berthold

. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998;1:352–6.

38.

Zalipsky

Lee

. Use of functionalized poly(ethylene glycol)s for modification of polypeptides. In: Harris

, ed. Poly(ethylene glycol) chemistry: biotechnical and biomedical applications. New York: Plenum Press, 1992:347–70.

39.

Site-directed pegylation of proteins. In: Shearwater Polymers, quarterly newsletter. Huntsville, AL: Shearwater Polymers, 1998:1–2.

40.

Delgado

Francis

Fisher

. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249–304.

41.

Fung

W-J

Porter

Bailon

. Strategies for the preparation and characterization of polyethylene glycol (PEG) conjugated pharmaceutical proteins. Polymer Preprints 1997;38:565–6.

42.

Zalipsky

Harris

. Introduction to chemistry and biological applications of poly(ethylene glycol). In: Harris

Zalipsky

, eds. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997:1–15.

43.

Working

Newman

Johnson

Cornacoff

. Safety of poly-(ethylene glycol) and poly(ethylene glycol) derivatives. In: Harris

Zalipsky

, eds. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997:45–59.

44.

Bendele

Seely

Richey

Sennello

Shopp

. Short communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998;42:153–7.

45.

Hershfield

. Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In: Harris

Zalipsky

, eds. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997:145–54.

46.

Hilman

Sorensen

. Management options: SCIDS with adenosine deaminase deficiency. Ann Allergy 1994;72:395–404.

47.

Hershfield

Buckley

Greenberg

Melton

Schiff

Hatem

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316: 589–96.

48.

Davis

Abuchowski

Van Es

Palczuk

Chen

Savoca

Enzyme-polyethylene glycol adducts: Modified enzymes with unique properties. Enzyme Engineering 1978;4:169–73.

49.

Davis

Abuchowski

Park

Davis

. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 1981;46:649–52.

50.

Keating

Holmes

Lerner

. L-Asparaginase and PEG asparaginase — past, present, and future. Leuk Lymphoma 1993;10(suppl): 153–7.

51.

Holle

. Pegaspargase: An alternative? Ann Pharmacother 1997;31: 616–24.

52.

Burnham

. Polymers for delivering peptides and proteins. Am J Hosp Pharm 1994;51:210–8.

53.

Tsutsumi

Tsunoda

Kamada

Kihira

Kaneda

Ohsugi

PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 1997;77:168–73.

54.

Campbell

Heimer

Ahmad

Eisenbeis

Lambros

Lee

Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. J Peptide Res 1997;49:527–37.

55.

Farese

Hunt

Grab

MacVittie

. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996;97:2145–51.

56.

Pardridge

Sakane

. Combined use of carboxyl-directed protein pegylation and vector-mediated blood—brain barrier drug delivery system optimized brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharmaceut Res 1998;15:576–82.

57.

Truitt

Tarby

Stern

Tamborini

Bontempo

Nalin

Pharmacodynamic and preliminary pharmacokinetic evaluation of pegylated derivatives of interferon-alfa 2a (abstract). Proceedings from the Annual Meeting of the American Association of Cancer Research, San Francisco, CA, April 10–13, 1994:398.

58.

Z-X

Hoffman

Patel

Joubert

. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects (abstract). Hepatology 1998;28(suppl):702.

59.

Nieforth

Nadeau

Patel

Mould

. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996;59:636–46.

60.

Lam

Neumann

Gretch

Wiley

Perelson

Layden

. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226–31.

61.

Algranati

Patel

Modi

. Cytochrome P450 (CYP)-mediated drug interactions are unlikely with peginterferon α-2a (PEG-IFN) except for CYP1A2 (abstract). Hepatology 1999;30(suppl):193A.

62.

Shiffman

Pockros

Reddy

Wright

Reindollar

Fried

A controlled, randomized, multicenter, descending dose Phase II trial of pegylated interferon alfa-2a (PEG) vs. standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C (abstract). Gastroenterology 1999;116:1275.

63.

Glue

Fang

Sabo

Rouzier-Panis

Raffanel

Gupta

Peg-interferon-alfa-2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data (abstract). Hepatology 1999;30(suppl): 189A.